Verrica Pharmaceuticals
在场
高管
查看带有其 14 名主要高管的组织结构图
Verrica Pharmaceuticals 搜索最多的简介
- Ted White, Director, President and Chief Executive Officer
- Sean Stalfort, Director
- Lawrence Eichenfield, Director
创建提醒
跟踪 Verrica Pharmaceuticals 的高管变动
药店
Verrica Pharmaceuticals 拥有 1,837 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Verrica Pharmaceuticals 的最新新闻稿
- Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP 315 an Investigational Oncolytic Peptide Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma - Verrica Pharmaceutica
- Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP 315 for the Treatment of Basal Cell Carcinoma on August 14 2024 - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories Inc. - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts - Verrica Pharmaceuticals
- View more press releases Close
通过电子邮件
